Takeda Pharmaceutical (TAK) Accounts Payables (2017 - 2026)

Takeda Pharmaceutical's Accounts Payables history runs 10 years deep, the most recent figure standing at $3.1 billion for Q1 2026.

• In Q1 2026, Accounts Payables rose 0.52% year-over-year to $3.1 billion; the TTM figure through Mar 2026 stood at $3.1 billion (up 0.52% YoY), while the FY2026 annual figure was $3.3 billion, up 4.56% from the prior year.
• Accounts Payables was $3.1 billion for Q1 2026 at Takeda Pharmaceutical, up from $3.0 billion in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $4.9 billion in Q1 2023 to a low of $2.7 billion in Q4 2022.
• Historically, Accounts Payables has averaged $3.2 billion across 5 years, with a median of $3.0 billion in 2025.
• The sharpest annual moves came in 2022 and 2024: Accounts Payables surged 36.76% in 2022, then retreated 24.73% in 2024.
• A 5-year view of Accounts Payables shows it stood at $2.7 billion in 2022, then advanced by 21.3% to $3.3 billion in 2023, then dropped by 7.49% to $3.0 billion in 2024, then advanced by 0.38% to $3.0 billion in 2025, then grew by 3.12% to $3.1 billion in 2026.
• The last three Accounts Payables figures came in at $3.1 billion (Q1 2026), $3.0 billion (Q4 2025), and $3.0 billion (Q3 2025), per Business Quant data.